Sprouty2 enhances the tumorigenic potential of glioblastoma cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Jong-Whi | - |
dc.contributor.author | Wollmann, Guido | - |
dc.contributor.author | Urbiola, Caries | - |
dc.contributor.author | Fogli, Barbara | - |
dc.contributor.author | Florio, Tullio | - |
dc.contributor.author | Geley, Stephan | - |
dc.contributor.author | Klimaschewski, Lars | - |
dc.date.accessioned | 2022-02-28T05:40:28Z | - |
dc.date.available | 2022-02-28T05:40:28Z | - |
dc.date.created | 2022-02-28 | - |
dc.date.issued | 2018-08 | - |
dc.identifier.issn | 1522-8517 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/83576 | - |
dc.description.abstract | Background. Sprouty2 (SPRY2), a feedback regulator of receptor tyrosine kinase (RTK) signaling, has been shown to be associated with drug resistance and cell proliferation in glioblastoma (GBM), but the underlying mechanisms are still poorly defined. Methods. SPRY2 expression and survival patterns of patients with gliomas were analyzed using publicly available databases. Effects of RNA interference targeting SPRY2 on cellular proliferation in established GBM or patient-derived GBM stemlike cells were examined. Loss-or gain-of-function of SPRY2 to regulate the tumorigenic capacity was assessed in both intracranial and subcutaneous xenografts. Results. SPRY2 was found to be upregulated in GBM, which correlated with reduced survival in GBM patients. SPRY2 knockdown significantly impaired proliferation of GBM cells but not of normal astrocytes. Silencing of SPRY2 increased epidermal growth factor-induced extracellular signal-regulated kinase (ERK) and Akt activation causing premature onset of DNA replication, increased DNA damage, and impaired proliferation, suggesting that SPRY2 suppresses DNA replication stress. Abrogating SPRY2 function strongly inhibited intracranial tumor growth and led to significantly prolonged survival of U87 xenograft-bearing mice. In contrast, SPRY2 overexpression promoted tumor propagation of low-tumorigenic U251 cells. Conclusions. The present study highlights an antitumoral effect of SPRY2 inhibition that is based on excessive activation of ERK signaling and DNA damage response, resulting in reduced cell proliferation and increased cytotoxicity, proposing SPRY2 as a promising pharmacological target in GBM patients. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | OXFORD UNIV PRESS INC | - |
dc.relation.isPartOf | NEURO-ONCOLOGY | - |
dc.title | Sprouty2 enhances the tumorigenic potential of glioblastoma cells | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000438338000006 | - |
dc.identifier.doi | 10.1093/neuonc/noy028 | - |
dc.identifier.bibliographicCitation | NEURO-ONCOLOGY, v.20, no.8, pp.1044 - 1054 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85051972241 | - |
dc.citation.endPage | 1054 | - |
dc.citation.startPage | 1044 | - |
dc.citation.title | NEURO-ONCOLOGY | - |
dc.citation.volume | 20 | - |
dc.citation.number | 8 | - |
dc.contributor.affiliatedAuthor | Park, Jong-Whi | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | DNA damage response | - |
dc.subject.keywordAuthor | ERK | - |
dc.subject.keywordAuthor | glioblastoma | - |
dc.subject.keywordAuthor | Sprouty2 | - |
dc.subject.keywordAuthor | replication stress | - |
dc.subject.keywordPlus | DOWN-REGULATION | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordPlus | PROLIFERATION | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | PATHWAY | - |
dc.subject.keywordPlus | GLIOMA | - |
dc.subject.keywordPlus | CONCOMITANT | - |
dc.subject.keywordPlus | MALIGNANCY | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.